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Abstract (232 words) 
 
Background   
The pro- and antiatherogenic roles of apolipoproteins B and A-I, respectively, are well-
established although the importance of apolipoprotein A-II remains unclear. There is 
extensive evidence for the involvement of plasma lipoproteins in haemostatic function. 
However, in vivo studies of relationships between haemostatic variables and 
apolipoprotein concentrations are very limited. 
Methods  
Plasma fibrinogen, factors VIIc and Xc (FVIIc and FXc, respectively), apolipoproteins 
(apo) A-I, A-II and B, triglycerides, total, low density and high density lipoprotein (HDL) 
cholesterol, and cholesterol in HDL subfractions 2 and 3 were measured in 186 
apparently healthy Caucasian men (aged 26-78y; body mass index 19.9-37.8 kg/m2). 
Associations between haemostatic, apolipoprotein, lipid and lipoprotein variables were 
explored in uni- and multivariable analyses. 
Results 
Fibrinogen did not correlate with any of the lipid-related variables. FVIIc and FXc were 
significant positive univariate correlates of total cholesterol (correlation coefficients 
0.26, p<0.001 and 0.19, p<0.05, respectively) triglycerides (0.37, p<0.001 and 0.36, 
p<0.001), and apoB (0.21, p<0.01 and 0.17, p<0.05) and apoA-II (0.19, p<0.05 and 
0.29, p<0.001). HDL2 subfraction cholesterol correlated negatively with FVIIc and FXc 
(-0.20, p<0.01 and -0.22, p<0.01, respectively). In multivariable analysis, only the 
associations of FVIIc and FXc with total cholesterol, triglycerides and apoA-II remained 
statistically significant. 
Conclusions 
Total cholesterol and triglycerides were the major independent lipid correlates of FVIIc 
and FXc. The independent and positive associations of apoA-II with FVIIc and FXc 
suggest a prothrombotic involvement for this apolipoprotein.  
 3
Key words: 
 
apolipoproteins; high density lipoprotein; lipids; apoA-II; Factor VII; Factor X; fibrinogen
 4
 
Introduction 
 
 The importance of lipoproteins and haemostasis in the aetiology of 
atherosclerosis is well established. Perturbation in the balance between coagulation 
and fibrinolysis can promote the development of atherosclerosis and a number of 
studies have shown that disturbances in lipoprotein metabolism can influence this 
balance 1. Triglycerides and very-low-density lipoprotein (VLDL) elevate Factor VII  
coagulant activity (FVIIc) and also impair fibrinolysis by increasing plasminogen 
activator inhibitor 1 (PAI-1) activity 2. Moreover, both VLDL and oxidized low density 
lipoprotein (LDL) support the assembly of the prothrombinase complex of 
phospholipids, calcium ions and coagulation factors V, X and II 3.  In contrast, the anti-
atherogenic lipoprotein, high density lipoprotein (HDL) has both anti-coagulatory and 
pro-fibrinolytic properties 4,5, perhaps due to an ability to inhibit VLDL-stimulated tissue 
factor synthesis 2 and activate factor X 6,7. 
 
The principal apolipoproteins of LDL and HDL are apolipoprotein B-100 (apo B-100) 
and apolipoprotein A-I (apo A-I), respectively and it has been suggested that these 
might provide better indices of atherosclerosis risk than the lipoprotein cholesterol 
concentrations 8,9. The importance of the second most prominent HDL apolipoprotein, 
apolipoprotein A-II (apo A-II), is less clear, with both pro- and anti-atherogenic 
properties having been described10,11.  In vitro studies suggest that the apolipoproteins 
may have discrete, mainly anti-coagulatory, interactions with the haemostatic system. 
For example, apo A-I and apo A-II can inhibit activation of Factor X by Factor VII and 
tissue factor 6,12 and apo A-I inhibits production of the prothrombinase complex by 
limiting the availability of anionic lipids on extracellular surfaces13. Moreover, apoB-100 
can inhibit tissue factor activation14.  However, in vivo approaches to understanding 
these relationships appear extremely limited. 
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The Heart Disease and Diabetes Risk Factors in a Screened Cohort Study (HDDRISC) 
is an open, occupational cohort study, which has included an unusually detailed range 
of risk factor measurements. In the present analysis we have investigated relationships  
between the haemostatic variables fibrinogen, FVIIc and factor X coagulant activity 
(FXc), the apolipoproteins apo A-I, apo A-II and apoB-100 as well as plasma 
triglycerides and total, LDL and HDL cholesterol.  
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Participants and Methods 
 
Design 
The Heart Disease and Diabetes Risk Indicators in a Screened Cohort (HDDRISC) 
Study is a cohort study of metabolic risk factors for the development of coronary heart 
disease and diabetes 15,16.  The study began in 1971 as a company health program, in 
the course of which participants received a range of metabolic, clinical and laboratory 
measurements. The present analysis concerns the 186 Caucasian male recruits who, 
between 1994 and 1998, had both apolipoproteins and haemostatic factors measured. 
Written, informed consent to the study was obtained in each case, and local research 
ethics committee approval was given. 
 
Procedures 
Participants were instructed to have fasted overnight (>12h), to have taken only water 
and refrained from cigarette smoking on the morning of their test.  Height and weight 
were measured and a clinical history was taken including details of exercise habits, 
smoking and alcohol consumption. The participants rested for 15 minutes in the semi-
recumbent position and their systolic and diastolic blood pressure were recorded using 
a mercury sphygmomanometer. An indwelling cannula was inserted into an antecubital 
vein in each arm. Blood samples were taken for fasting plasma measurements. All 
samples were kept on ice before separation of plasma, which took place within 1 hour 
of the sample being taken. Samples for routine biochemical measurements were 
stored at 4˚C before analysis. Plasma samples for measurement of haemostatic 
factors were frozen immediately.  
 
Laboratory Measurements 
Plasma levels of fibrinogen, FVIIc and FXc were measured by single-stage clotting 
assays using human factor VII- or factor X-deficient plasma and recombinant human 
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tissue factor with coagulant activity quantified by prothrombin time-based 
nephelometry using reagents and an automated ACL 100 coagulation analyser 
supplied by Instrumentation Laboratory (Lexington, MA, U.S.A.).  Apolipoproteins A-I, 
A-II and B (predominantly apoB-100, since samples were taken in the fasted state) were 
measured by immunoturbidimetry-based commercial kits (Immuno AG, Vienna, 
Austria) using a Cobas Mira discrete analyzer (Roche, Basel, Switzerland). Serum 
total cholesterol, triglycerides, HDL and LDL cholesterol concentrations were 
measured as described previously 15. Concentrations of HDL and HDL subclass 3 
(HDL3) cholesterol were measured after sequential precipitation with heparin and 
manganese ions 17 and dextran sulfate 18, respectively. The serum concentration of 
HDL subclass 2 (HDL2) cholesterol was calculated as the difference between the HDL 
and HDL3 cholesterol levels. Quality control was continuously monitored with 
commercially available lyophilized sera and by participation in national quality-control 
programs. Between batch assay coefficients of variation were: fibrinogen 7%; FVIIc 
7%; FXc 4%; apolipoprotein A-I 3-4%; apolipoprotein A-II 1-3%; apolipoprotein B 2-
4%; serum total cholesterol and triglycerides 1-2%; HDL cholesterol 2-4%; HDL3 
cholesterol 5-7%. 
  
Data analysis 
For entry in correlation and regression analyses, cigarette smoking was categorized 
as: never smoked/ex-smokers (0), or less than 5 (1), 5-14 (2), 14-24 (3), or more than 
24 (4) cigarettes/day. Alcohol intake was expressed as units consumed per week (a 
unit of alcohol approximates 10 ml or 8 g pure ethanol and is the amount contained in 
a half-pint (284 ml) of beer, a single glass (125 ml) of table wine, or a single measure 
(25 ml) of spirits). Exercise habit was expressed as none (0), moderate (1), or aerobic 
(2). Statistical analyses were carried out using STATA 8 (Stata Corporation, College 
Station, Texas, USA). Fibrinogen, triglycerides, HDL cholesterol and HDL3 cholesterol 
were logarithmically transformed and HDL2 cholesterol, was square-root transformed to 
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normalize their distributions. Pearson correlation was used to explore univariate 
associations between haemostatic and other continuous variables and multiple linear 
regression was used to confirm the independence of significant associations detected.  
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Results 
 
The 186 participants had a mean age of 49.4 years (range 26-78 years) and a mean 
BMI of 26.3 kg/m2 (range 19.9-37.8 kg/m2). All participants were free of diabetes 
(maximum fasting plasma glucose 6.1 mmol/l) and cardiovascular disease. Eighty-six 
percent of participants (n=159) had never smoked or were ex-smokers at the time of 
testing. Eighty-two percent of participants took no alcohol or described themselves as 
light irregular drinkers. Eighteen percent drank regularly up to 28 U/wk and only a 
single individual drank more than 28 U/wk. Forty-four percent of participants did not 
exercise at all whereas 41% were engaged in moderate exercise and 16% took 
aerobic exercise. Two individuals were taking lipid-lowering agents (both statins), 11 
were taking blood pressure-lowering agents and 3 uric-acid lowering agents. Two 
individuals reported regular aspirin use. Median and interquartile ranges for study 
variables are shown in Table 1.  
  
The strongest univariate correlate of fibrinogen (Table 2) was age (p<0.001) with 
cigarette smoking also a positive correlate (p<0.05). In contrast, neither FVIIc nor FXc 
were significantly related to age or cigarette smoking. FVIIc and FXc were, however, 
strongly positively correlated with BMI and also with systolic and diastolic blood 
pressure and were negatively correlated with exercise. In contrast, fibrinogen was only 
weakly associated with BMI, showed weaker correlations with blood pressure and did 
not correlate with exercise. Fibrinogen and FXc, but not FVIIc, were positively 
correlated with alcohol intake. 
 
Fibrinogen did not correlate with any of the lipid or lipoprotein-related variables (Table 
2). Both FVIIc and FXc were positively correlated with apo B, apo A-II, total cholesterol 
and triglycerides and were negatively correlated with HDL2 cholesterol. Neither FVIIc 
nor FXc correlated with apo A-I, LDL cholesterol or HDL3 cholesterol. Median FVIIc 
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and FXc in successive tertiles of apo A-II concentration are illustrated in Figure 1. On 
analysis of variance there was, as expected from the correlations described above, 
significant variation between tertiles of FVIIc (p=0.01) and FXc (p=0.001). Mean FVIIc 
and FXc in the two upper tertiles of apo A-II both differed significantly from the mean in 
the lowest tertile (FVIIc: p= 0.02 and p=0.009, respectively; FXc: p=0.01 and 
p=0.0004, respectively). Mean FVIIc and FXc did not differ significantly between the 
two upper tertiles of apo A-II (p=0.7 and p=0.3, respectively). 
 
In multiple linear regression analysis, with age, BMI, alcohol intake, exercise habit and 
current smoking included as predictor variables (Table 3), apo A-II, total cholesterol 
and triglycerides remained significant predictors of both FVIIc and FXc, whereas HDL2 
cholesterol and apo B ceased to be significant. With age, BMI, alcohol intake, exercise 
habit and current smoking included, there was a 3- to 4-fold reduction in the magnitude 
of the regression coefficient for HDL2 cholesterol as a predictor of FVIIc and FXc. In 
further multiple regression analyses (results not shown) this reduction in the magnitude 
of the regression coefficients was found to be almost entirely due to the effect of BMI 
and an even greater reduction was seen with inclusion of triglycerides in the model in 
place of BMI. BMI and triglycerides predicted FVIIc and FXc independently of one 
another. 
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Discussion 
 
A number of previous studies have explored relationships between haemostatic factors 
and lipoprotein concentrations and a few have included measurements of both 
haemostatic factors and apo A-1 and apo-B 19-22. However, in these studies, 
apolipoproteins have generally been evaluated as cardiovascular risk markers, and 
there remains relatively little information on their relationships with haemostatic factors. 
The present study is, to the best of our knowledge, the first in humans in vivo to 
examine specifically relationships between haemostatic factors and a range of the 
principal apolipoproteins that includes apo A-II. We found positive associations 
between apo B and apo A-II and FVIIc and FXc, but only the associations with apo A-II 
were fully independent. It was also noteworthy that total cholesterol and triglycerides 
were independently associated with FVIIc and FXc and that fibrinogen showed no 
associations with variables related to lipid metabolism. These findings were made in a 
group of apparently healthy Caucasian males, free of diabetes and cardiovascular 
disease and at relatively low risk of developing these conditions. Whether they are 
equally present in women, other ethnic groups or in at-risk or disease states remains 
to be established. 
 
Our principal novel finding is the independent, positive in vivo association between apo 
A-II and FVIIc and FXc. For FXc, this contrasts with the relationship that would 
expected on the basis of the in vitro demonstration that apo A-II can inhibit factor X 
activation 6,12. Nevertheless, there are several potential explanations for the positive 
relationship we observed. For example, a specific property of apo A-II that could affect 
FVIIc and FXc is its ability to displace the antioxidant enzyme paraoxonase from HDL 
particles 23 and render them proinflammatory 24. Paraoxonase protects LDL from lipid 
peroxidation 25 and increased LDL oxidation can reduce the activity of LDL-bound 
tissue factor pathway inhibitor 14, 26. This would be expected to increase the activation 
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of the extrinsic pathway and increase FVIIc and FXc. Simultaneous measurement of 
lipid peroxidation, paraoxonase activity, apolipoproteins and haemostatic factors will 
be needed to explore whether these relationships are mediating the association 
between apo A-II and FVIIc and FXc. 
 
Insulin resistance could be a common factor linking apo A-II with FVIIc and FXc. We 
have previously reported positive associations between insulin resistance and FVIIc 
and FXc in this cohort 27 and a number of reports describe links between insulin 
resistance and apo A-II. Mice overexpressing apo A-II have increased insulin 
resistance 28 and the converse is true of mice under-expressing apo A-II 29. Against 
this, mice over-expressing human as opposed to murine apo A-II do not appear to 
become insulin resistant in response to an atherogenic diet 30. However, there is 
evidence for links between apo A-II and the insulin resistant state of diabetes 31, 
including a positive feedback cycle between increased apo A-II production and the 
metabolic disturbances of diabetes 32. Simultaneous measurement of insulin 
sensitivity, apolipoproteins and haemostatic factors will be needed to confirm whether 
or not insulin resistance is mediating the association between apo A-II and FVIIc and 
FXc. 
 
Another potential explanation for associations between apo A-II and FVIIc and FXc 
might be found in links between haemostasis and triglyceride metabolism. In vitro 
studies indicate that apo A-II can suppress lipolysis of VLDL and consequently 
increase triglyceride concentrations 33, 34. A positive association between triglyceride 
levels and the activity of vitamin K-dependent clotting factors, including FVIIc and FXc, 
has been recognised for many years 35 and the role of high VLDL concentrations and 
consequently high triglyceride levels in the activation of factor VII is well-established 36. 
Activation of FVIIc and FXc by lipoproteins has been most strikingly demonstrated in 
the postprandial state 37 and there are reports that a polymorphism in the apo A-II gene 
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promotor associated with lower levels of apo A-II is also associated with reduced 
postprandial triglyceride-rich lipoprotein metabolism 38, 39. The association we found 
between apo A-II and FVIIc and FXc was independent of accompanying triglyceride 
concentrations, suggesting that triglyceride-rich lipoprotein metabolism is not the 
common factor between the positive association we observed between apo A-II and 
FVIIc and FXc. However, it is possible that the measurements we made did not 
encompass aspects of postprandial triglyceride metabolism that might still have a 
mediating role, for example remnants of triglyceride-rich lipoprotein metabolism 40. 
Simultaneous measurement of triglyceride-rich lipoproteins, apolipoproteins and 
haemostatic factors in the postprandial state will be needed to confirm whether 
postprandial triglyceride metabolism can mediate the association between apo A-II and 
FVIIc and FXc. 
 
Activation of factor VII by VLDL appears to be mediated by increased availability of 
phospholipids 36 and this also appears to be important in the activation of factor X 41. 
Apo A-II can directly stimulate ATP binding cassette transporter 1 (ABCA1)-mediated 
efflux of phospholipids and free cholesterol 42, which could contribute to activation of 
factors VII and X and the positive association we observed between apo A-II and FVIIc 
and FXc.  Another possible connection might be the ability of peroxisome proliferator-
activated receptor-α to upregulate both ABCA1 expression 43 and apo A-II gene 
transcription 44. However, these potential mechanisms derive from animal studies and 
apply equally to apo A-I and we found no relationship between apo A-I and FVIIc and 
FXc. Although traces of apo-AII may be synthesised in the intestine, the majority 
appears to be synthesised in the liver 45. Hepatic metabolism could play a role in the 
associations we observed and, in contrast to previous studies 46, a positive relationship 
between liver steatosis and apo A-II has now been reported in patients with chronic 
hepatitis C 47. However, liver disease tends to be associated with low levels of 
activated factor VII 48. 
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As yet, therefore, there is no definitive mechanism linking apo A-II levels with FVIIc 
and FXc although there remains the possibility that, rather than apo A-II affecting FVIIc 
and FXc, these coagulation factors are affecting apo A-II levels. Genetic 
polymorphisms were not evaluated in our study. Nevertheless, this possibility could be 
explored in further studies in relation to genetic variation at residue 353 of factor VII 
which, in the Arg353 variant, is associated with both higher factor VII antigen levels 
and higher FVIIc 49. Investigation of this possibility would be complex, however, given 
the marked interaction between factor VII genotype and triglyceride concentrations 49 
and the associations mentioned above between triglyceride metabolism and apo A-II.   
 
It is important to note that our novel findings with regard to apo A-II are supported by 
our confirmation of other associations previously reported by others. These include the 
positive associations of FVIIc and FXc with total cholesterol and triglycerides 50, 51 but 
not with LDL or HDL 2,52. Also in agreement with our findings with regard to fibrinogen 
some previous studies found no significant associations between fibrinogen and serum 
lipids and lipoproteins 2,53. However, in large population studies, fibrinogen has been 
weakly and positively associated with total and LDL cholesterol, and weakly and  
negatively associated with HDL cholesterol 54-56. It is possible that similarly weak 
associations are present in the cohort we studied, but larger numbers would have 
been needed to demonstrate them as significant.  
 
In contrast to the negative association expected from in vitro studies 14, we found a 
positive association between apo B and FVIIc and FXc. We also found a negative 
relationship between HDL2 cholesterol and haemostatic factor activities, but no 
association with the principal apolipoprotein of HDL2, apo A-I. Both the associations of 
apo B and HDL2 cholesterol with haemostatic factors ceased to be significant after the 
adjustment of BMI or triglycerides. Triglyceride-rich lipoproteins, including VLDL, 
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contain apo B and HDL2 cholesterol is strongly inversely related to triglycerides. On the 
basis of these findings, we would maintain that the well-established effect of VLDL and 
triglycerides on FVIIc and FXc underlies the associations we observed between apo B 
and HDL2 cholesterol and haemostatic factors. Further analysis showed that BMI 
predicted FVIIc and FXc independently of triglycerides, which accords with additional 
roles for adiposity in haemostasis beyond its accompanying high VLDL and triglyceride 
levels. 
 
In summary, we found no evidence for strong associations between lipid-related 
variables and fibrinogen. Neither were there significant, independent, relationships 
between apo A-1, HDL and HDL subfraction cholesterol concentrations and 
haemostatic variables. Significant associations between apolipoproteins and 
haemostatic factors nevertheless extend to apo B and apo A-II and FVIIc and FXc but 
of these only the associations with apo A-II were independent of age, BMI and lipid 
and lipoprotein cholesterol concentrations. The mechanism for this association is, at 
present, unclear. 
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Table 1. Group characteristics (median and interquartile range) for 186 apparently 
healthy Caucasian males 
 
 
Variable 
 
Median (IQ range)
Age (y) 49.3  (43.7-56.0) 
BMI (kg m-2) 26.0 (24.2-28.1) 
systolic BP (mmHg) 125 (115-135) 
diastolic BP (mmHg) 80 (75-85) 
Fibrinogen (mg/dl) 272.5 (234-313) 
Factor VII (%) 115.5 (98-129) 
Factor X (%) 113.0 (103-126) 
apolipoprotein B (mg/dl) 77.0 (64-90) 
apolipoprotein A1 (mg/dl) 119 (109-134) 
apolipoprotein A-II (mg/dl) 39 (36-43) 
Total cholesterol (mmol/l) 5.30 (4.69-6.03) 
Triglycerides (mmol/l) 1.39 (0.91-2.08) 
LDL cholesterol (mmol/l) 3.27 (2.65-3.94) 
HDL cholesterol (mmol/l) 1.26 (1.08-1.51) 
HDL2 cholesterol (mmol/l) 0.41 (0.29-0.58) 
HDL3 cholesterol (mmol/l) 0.83  (0.73-0.93) 
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Table 2. Univariate Pearson correlations (R) between individual characteristics, lipids, 
lipoproteins and apolipoproteins and haemostatic factors 
  
 Fibrinogen* Factor VIIc Factor X 
Age  0.32c -0.05 -0.05 
BMI  0.140.05  0.33c  0.30c 
Smoking  0.15a  0.02  0.130.08 
Alcohol  0.17a  0.05  0.15a 
Exercise -0.12 -0.14a -0.140.05 
Systolic BP  0.16a  0.24b  0.17a 
Diastolic BP  0.05  0.28c  0.16a 
Apolipoprotein B  0.09  0.21b  0.17a 
Apolipoprotein A1 -0.01 -0.04 -0.02 
Apolipoprotein A-II -0.10  0.19a  0.29c 
Total cholesterol  0.02  0.26c  0.19a 
Triglycerides* -0.01  0.37c  0.36c 
LDL cholesterol  0.01  0.12 0.09  0.05 
HDL cholesterol* -0.05 -0.11 -0.10 
HDL2 cholesterol† -0.07 -0.20b -0.22b 
HDL3 cholesterol* -0.02  0.07  0.130.06 
 
Significances: a p<0.05; b p<0.01; c p<0.001. Borderline significances (p<0.1) are also 
given 
*   log transformed data 
† square-root transformed data 
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Table 3. Univariate regression coefficients for prediction of Factor VII and X activities 
by lipids, lipoproteins and apolipoproteins that were significant correlates of FVIIc and 
FXc, and multivariate regression coefficients for lipids, lipoproteins and apolipoproteins 
plus the potential confounding factors age, body mass index (BMI), cigarette smoking , 
alcohol intake and exercise habit as predictors.  
 
dependent 
variable predictor variable 
univariate 
regression 
coefficient  
(lipid-related 
predictors alone) 
multivariate 
regression 
coefficient  
(lipid-related 
predictors plus age, 
BMI, smoking, 
alcohol and 
exercise) 
Factor VII Apolipoprotein B 0.27b 0.17 
 Apolipoprotein A-II 0.80b 0.61a 
 Total cholesterol 6.38c 4.78b 
 Triglycerides* 15.58c 12.02c 
 HDL2 cholesterol† -28.79b -7.19 
Factor X Apolipoprotein B 0.15a 0.10 
 Apolipoprotein A-II 0.84c 0.62b 
 Total cholesterol 3.19a 2.55a 
 Triglycerides* 10.19 c 7.14 b 
 HDL2 cholesterol† -22.03b -8.73 
 
Significances: a p<0.05; b p<0.01; c p<0.001. 
 *   log transformed data 
† square-root transformed data 
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Legend to  Figure 1 
 
Medians and inter-quartile ranges for Factor VII and Factor X coagulant activity in 
successive tertile ranges of apolipoprotein A-II (apo A-II) concentration. 
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